The company's gene editing and genome engineering platform offers techniques for the development of human-compatible organs, tissues, and cells, which can solve the global organ crisis by providing an alternative to allotransplantation. eGenesis addresses both the key virology and immunology hurdles that have impeded the advancement of xenotransplantation and is uniquely positioned to revolutionize the field with a multiplexed gene editing platform. Their goal is to provide commercially-viable products that save and enhance the lives of patients worldwide.